Pharma Licensing & Partnerships
Latest in Pharma Licensing & Partnerships· Oct 29
Merck raised its full-year profit forecast after Keytruda sales exceeded expectations, driven by strong demand for a newly launched formulation of the cancer immunotherapy. The guidance increase reflects confidence in near-term revenue and margin expansion, demonstrating sustained pricing power in oncology despite competitive pressures in the space.
Pharmaceutical company licensing deals, strategic partnerships, and capital-raising activities reshaping drug development pipelines and market positioning.
3 events tracked
- Single source13 days ago
Novartis faces fresh patent cliff as pipeline drugs stumble in trials
Pharmaceutical company faces sequential patent expirations, with revenue loss from one drug offset by upcoming exclusivity cliff for another.
CNBC
- Single source14 days ago
Merck raises profit forecast after Keytruda sales beat expectations
Merck beats quarterly estimates and raises full-year profit guidance, driven by strong sales of a new Keytruda formulation.
CNBC
- Single sourceabout 1 month ago
Novo Nordisk inks second licensing agreement after investor pushback
Novo Nordisk signs second licensing deal following recent investor relations setback.
MarketWatch